Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$73.78 USD
-0.56 (-0.75%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $73.77 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$73.78 USD
-0.56 (-0.75%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $73.77 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
Zacks News
Is VanEck Morningstar Wide Moat ETF (MOAT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for MOAT
Gilead (GILD) Q2 Earnings & Sales Top, Revenue Outlook Upped
by Zacks Equity Research
Gilead (GILD) reports better-than-expected second quarter results on strong HIV business. The company also raises its annual revenue guidance.
Should VanEck Morningstar Wide Moat ETF (MOAT) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for MOAT
Gilead Sciences (GILD) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Gilead (GILD) delivered earnings and revenue surprises of 4.64% and 6.55%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Is a Beat in Store for BioNTech (BNTX) This Earnings Season?
by Zacks Equity Research
On BioNTech's (BNTX) second-quarter earnings call, investors are expected to focus on the sales performance of its COVID-19 vaccine, Comirnaty, developed in partnership with Pfizer.
Drug, Biotech Stocks' Q2 Earnings on Aug 2: GILD, INCY & More
by Zacks Equity Research
Let's check out how the four pharma/drug/biotech companies are placed before the quarterly earnings release on Aug 2.
Viatris (VTRS) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on top-line and bottom-line numbers when Viatris (VTRS) reports second-quarter results.
Exelixis (EXEL) to Post Q2 Earnings: What is in the Cards?
by Zacks Equity Research
Investors will likely focus on the demand for Cabometyx and pipeline updates when Exelixis (EXEL) reports Q2 results. Operating expenses might have jumped.
Novo Nordisk (NVO) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Novo Nordisk's (NVO) top line is likely to have been driven by sales of its Diabetes and Obesity Care products in the second quarter of 2022.
Is a Surprise Coming for Gilead Sciences (GILD) This Earnings Season?
by Zacks Equity Research
Gilead Sciences (GILD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
What is in Store for Regeneron (REGN) This Earnings Season?
by Zacks Equity Research
Regeneron's (REGN) second-quarter earnings might have gotten a boost from the solid performance of Eylea and Dupixent.
Is a Beat in Store for Gilead (GILD) in This Earnings Season?
by Zacks Equity Research
Investors will focus on the HIV franchise's performance and Veklury sales in Gilead's (GILD) second-quarter 2022 results.
Biotech Stock Roundup: BMY, BIIB's Q2 Earnings, GILD's Updates & More
by Zacks Equity Research
Earnings updates from Bristol Myers (BMY) and Biogen (BIIB) are a few key highlights from the biotech sector during the past week.
Will AstraZeneca (AZN) Deliver a Beat This Earnings Season?
by Zacks Equity Research
Strong demand trends for AstraZeneca's (AZN) key drugs, Lynparza, Tagrisso, Imfinzi and Farxiga are likely to have driven the top line in the second quarter.
Earnings Preview: Bionano Genomics, Inc. (BNGO) Q2 Earnings Expected to Decline
by Zacks Equity Research
Bionano Genomics, Inc. (BNGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gilead Sciences (GILD) Stock Moves -0.21%: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $60.62, moving -0.21% from the previous trading session.
Should You Buy Beaten-Down Biotech Stocks & ETFs?
by Neena Mishra
We highlight 4 ETFs that have started rebounding after a brutal sell-off
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gilead (GILD) Gets Positive CHMP Opinion for Veklury & Tecartus
by Zacks Equity Research
Gilead (GILD) receives positive CHMP opinion for full marketing authorization of its COVID-19 Jab, Veklury, and for using its CAR-T cell therapy Tecartus to treat relapsed or refractory B-cell precursor ALL in adults.
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $61.55 in the latest trading session, marking a -0.92% move from the prior day.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
Humanigen (HGEN) Plunges as COVID Study Fails to Meet Goal
by Zacks Equity Research
The NIAID's ACTIV-5/BET-B study evaluating Humanigen's (HGEN) lenzilumab plus remdesivir in hospitalized COVID-19 patients fails to meet the primary endpoint. Stock down.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Gilead Sciences (GILD) Stock Moves -0.51%: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $62.34, marking a -0.51% move from the previous day.
VERU's Shares Jump on Successful COVID-19 Study Results
by Zacks Equity Research
VERU gains on the success of its late stage study evaluating the efficacy and safety of oral sabizabulin 9 mg for COVID-19.